UMB-136

Cat. No.:	HY-119490
CAS No.:	2109805-83-4
Molecular Formula:	$C_{24}H_{27}N_5O_2$
Molecular Weight:	417.5
Target:	Epigenetic Reader Domain; HIV
Pathway:	Epigenetics; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb[1].
In Vitro	UMB-136 (5 μM; 24 h) significantly induces HIV-1 reactivation[1]. UMB-136 (2.5 μM; 24 h) enhances HIV-1 transcription and viral production by releasing P-TEFb[1]. UMB-136 (2.5 or 5 μM) reverses HIV-1 latency in multiple cell models (THP89GFP, J-Lat full-length (dEnv) clones, primary CD4+ T cell) of HIV-1 latency[1]. UMB-136 (2.5 μM) synergizes with other LRAs (Prostratin HY-107421 or SAHA) to reverse HIV-1 latency in J-Lat cell lines[1]. Combined treatment with UMB-136 (2.5 μM) and PKC activators reverses HIV-1 latency in patient-derived resting CD4+ T cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Huang H, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Front Microbiol. 2017 Jun 7;8:1035.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA